Related Experiment Video

Updated: May 22, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Improving survival and limiting toxicity: latest advances in treating human epidermal growth factor receptor 2

Vandana G Abramson1, Ingrid A Mayer

  • 1Department of Medicine and Breast Cancer Research Program, Vanderbilt-Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.

Therapeutic Advances in Medical Oncology
|May 17, 2012
PubMed

Insights

New breast cancer treatments target human epidermal growth factor receptor 2 (HER2) pathways. Research aims to improve HER2-targeted therapies like trastuzumab, enhancing patient survival while reducing chemotherapy toxicity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Breast cancer treatment has advanced through targeted therapies, particularly for HER2-overexpressing tumors.
  • Human epidermal growth factor receptor 2 (HER2)-targeted agents have significantly improved survival rates.
  • Current standard treatment combines chemotherapy with HER2-targeted agents, often leading to substantial toxicities.

Purpose of the Study:

  • To review recently investigated agents for HER2-overexpressing breast cancer.
  • To enhance response magnitude and duration to trastuzumab-based treatments.
  • To minimize treatment-related toxicities in patients with HER2-overexpressing breast cancer.

Main Methods:

  • Review of recent clinical trials and investigational agents for HER2-overexpressing breast cancer.
  • Analysis of treatment strategies focusing on duration, drug combinations, and toxicity profiles.
  • Exploration of biomarkers for predicting resistance to HER2-targeted therapy.

Main Results:

  • The field of HER2-overexpressing breast cancer treatment is rapidly evolving, making specific recommendations challenging.
  • Trastuzumab-based treatment combined with chemotherapy remains the standard, despite associated toxicities.
  • Ongoing research focuses on optimizing existing therapies and identifying new treatment approaches.

Conclusions:

  • Further research is crucial to improve outcomes for patients with HER2-overexpressing breast cancer.
  • Investigating therapy duration, drug combinations, and resistance biomarkers will reduce morbidity and mortality.
  • The ultimate goal is to maximize treatment benefits while minimizing adverse effects for improved patient survival and quality of life.
Keywords:
HER2 overexpressingbreast cancerhuman epidermal growth factor receptor 2lapatinibpertuzumabtrastuzumabtrastuzumab emtansine

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...